WO2015122717A1 - Nouvelles bactéries d'acide lactique possédant un effet inhibiteur sur l'obésité et leur utilisation - Google Patents

Nouvelles bactéries d'acide lactique possédant un effet inhibiteur sur l'obésité et leur utilisation Download PDF

Info

Publication number
WO2015122717A1
WO2015122717A1 PCT/KR2015/001480 KR2015001480W WO2015122717A1 WO 2015122717 A1 WO2015122717 A1 WO 2015122717A1 KR 2015001480 W KR2015001480 W KR 2015001480W WO 2015122717 A1 WO2015122717 A1 WO 2015122717A1
Authority
WO
WIPO (PCT)
Prior art keywords
obesity
lactobacillus
lactic acid
acid bacteria
extract
Prior art date
Application number
PCT/KR2015/001480
Other languages
English (en)
Korean (ko)
Inventor
한명주
김동현
Original Assignee
경희대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 경희대학교 산학협력단 filed Critical 경희대학교 산학협력단
Publication of WO2015122717A1 publication Critical patent/WO2015122717A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/121—Brevis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/24—Lactobacillus brevis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum

Definitions

  • the present invention relates to a novel lactic acid bacterium having an obesity inhibitory effect and its use, and more particularly, it is isolated from kimchi, and has various novel functions such as obesity inhibitory effect, blood cholesterol lowering effect, blood triglyceride lowering effect, antioxidant effect, and the like. It relates to the use of the prophylaxis, amelioration or treatment of lactic acid bacteria and obesity or obesity-related diseases.
  • Obesity is a metabolic disease caused by an imbalance between calorie intake and consumption and is morphologically caused by hypertrophy or hyperplasia of fat cells in the body. Obesity is not only the most common malnutrition in Western society, but the importance of treatment and prevention has been highlighted in recent years in Korea, as the frequency of obesity is rapidly increasing due to the improvement of dietary life and the westernization of lifestyle. have. Obesity is an important factor that not only psychologically diminishes individuals but also increases the risk of developing various adult diseases.
  • Obesity is known to be directly related to the increased prevalence of various adult diseases, such as type 2 diabetes, hypertension, hyperlipidemia, and heart disease (Cell 87: 377, 1999), and the combination of obesity-related diseases together with metabolic syndrome or insulin resistance It is called syndrome (insulin resistance syndrome), and these have been found to be the cause of atherosclerosis and cardiovascular disease. It can be inferred that fat-rich fat cells mediate this phenomenon by the fact that obesity increases the incidence of various metabolic diseases and actual weight loss significantly reduces the incidence of these diseases.
  • adipose tissue was only thought of as an energy storage organ that stores excess energy in the form of triglyceryl (triacylglycerol) and releases it when needed, but recently, adiponectin, leptin, and resistin Various adipokines are accepted as important endocrine organs that regulate the homeostasis of energy (Trends Endocrinol Metab 13:18, 2002). Therefore, understanding of the proliferation of fat cells and the substances secreted from fat cells and their in vivo regulation mechanisms are expected to be the foundation for understanding obesity and various diseases and developing effective treatments.
  • adipocyte differentiation Studies on the regulation of adipocyte differentiation are being actively conducted, and the main mechanism is that differentiation from preadipocytes in the body is associated with increased adipocyte derivation in obese patients.
  • the process of differentiation of pro-adipocytes into adipocytes has been studied using cells such as 3T3-L1, and several transcription factors, especially transcription factors known to be involved in localization, C / EBPs (CAAT enhancers). It is known that binding proteins, PPARs (Peroxisome Proliferator Activated receptor) and ADD / SREBPs (Adipocyte determination and differentiation dependent factor 1 / sterol response element binding proteins) are expressed over time and regulate the process (Bart A Jessen).
  • PPARs Peroxisome Proliferator Activated receptor
  • ADD / SREBPs Adipocyte determination and differentiation dependent factor 1 / sterol response element binding proteins
  • PPAR ⁇ is a particularly important transcription factor for adipocyte differentiation, and forms dimers with the retinoic acid X receptor protein (RXR), which is present in the promoters of various adipocyte genes. Binds to peroxisome proliferator response elements (Tontonoz PE et al., Genes Dev., 8, pp1224-1234, 1994; Hwang, C. S et al., Cell Dev. Biol., 13, pp873-877) .
  • RXR retinoic acid X receptor protein
  • PPAR ⁇ The interaction of PPAR ⁇ with C / EBP ⁇ is critical for differentiation into mature adipocytes. These transcription factors and adipocyte regulatory factors promote differentiation into adipocytes, and ap2 (adipocyte fatty acid-binding protein 2) The expression levels of fat cell specific proteins such as and fat metabolizing enzymes such as fat acid synthase (Fas) are increased.
  • ADD1 / SREBPs play an important role in fat metabolism, but are also known to be involved in the differentiation process. Expression of ADD1 / SREBP1c in immature adipocytes is believed to contribute to the activation of PPAR ⁇ (Rosen ED et al., Annu. Rev. Cell Dev.
  • Lactobacillus has been reported to show the effects of maintaining normal intestinal flora, improving intestinal flora, antidiabetic and antihyperlipidemic effects, inhibiting carcinogenesis, inhibiting colitis, and nonspecific activity of the host's immune system.
  • the strain Lactobacillus is a major member of the normal microbial community in the human intestine, which has long been known to be important for maintaining a healthy digestive system and the vaginal environment, and the US Public Health Service (US Public Health Service). guidelines) are currently classified as 'Bio-safty Level 1', where none of the Lactobacillus strains currently deposited with the American Strain Deposit Organization (ATCC) is known about the potential risk of causing disease in humans or animals. have.
  • ATCC American Strain Deposit Organization
  • kimchi lactic acid bacteria are reported to have the effect of immuno-enhancing, anti-microbial, antioxidant, anti-cancer, anti-obesity, hypertension or constipation as a lactic acid bacteria involved in kimchi fermentation [Hivak P, Odrska J, Ferencik M, Ebringer L, Jahnova E, Mikes Z .: One-year application of Probiotic strain Enterococcus facium M-74 decreases Serum cholesterol levels. Bratisl lek Listy 2005; 106 (2); 67-72; Agerholm-Larsen L. Bell ML. Grunwald GK.
  • Astrup A The effect of a probiotic milk product on plasma cholesterol: a metaanalysis of short-term intervention studies; Eur J Clin Nutr. 2000; 54 (11) 856-860; Renato Sousa, Jaroslava Helper, Jian Zhang, Strephen J Lewis and Wani O Li; Effect of Lactobacillus acidophilus supernants on body weight and leptin expression in rats; BMC complementary and alternative medicine. 2008; 8 (5) 1-8].
  • 10-2012-0034482 discloses Lactobacillus plantarum KY1032 (Accession No .: KCCM-10430) having an inhibitory effect on 3T3-L1 adipocyte differentiation
  • Korea Korean Patent Laid-Open Publication No. 10-0996577 discloses a novel Lactobacillus curvatus HY7601 (Accession No .: KCTC 11456BP) having a blood cholesterol lowering effect and an anti-obesity effect
  • Korean Patent Publication No. 10-2013 -0046896 discloses a composition for the prevention and treatment of obesity, including Lactobacillus plantarum DSR920 (Accession Number: KCCM 11210P) as an active ingredient, Korean Patent Publication No.
  • the present invention is derived under such a conventional background, and an object of the present invention is to provide a novel lactic acid bacteria having various functionalities such as anti-obesity activity.
  • Another object of the present invention is to provide various uses of the novel lactic acid bacteria.
  • the inventors of the present invention screen countless lactic acid bacteria from kimchi or human feces, and among them, certain Lactobacillus strains are excellent for preventing or treating obesity-induced model animals. It was found that it had an effect, and the present invention was completed.
  • the present invention is Lactobacillus brevis ( Lactobacillus brevis ) comprising the nucleotide sequence of SEQ ID NO: 1 as 16S rDNA, Lactobacillus company comprising the nucleotide sequence of SEQ ID NO: 2 as 16S rDNA Lactobacillus plantarum (K) ( Lactobacillus sakei ) and Lactobacillus plantarum ( Lactobacillus plantarum ) comprising the nucleotide sequence of SEQ ID NO: 4 in 16S rDNA, Lactic acid bacterium selected from the group consisting of lactic acid bacteria, anti-obesity activity, blood cholesterol lowering activity To provide lactic acid bacteria having a neutral lipid lowering activity or antioxidant activity in the blood.
  • the Lactobacillus brevis ( Lactobacillus brevis ) is preferably Lactobacillus brevis ( Lactobacillus brevis ) OK56 (Accession Number: KCCM 11516P).
  • the Lactobacillus sakei ( Lactobacillus sakei ) is preferably Lactobacillus sakei ( Lactobacillus sakei ) OK101 (Accession Number: KCCM 11664P).
  • the Lactobacillus plantarum ( Lactobacillus plantarum ) is preferably Lactobacillus plantarum OK169 (Accession Number: KCCM 11663P).
  • one example of the present invention is Lactobacillus brevis comprising the nucleotide sequence of SEQ ID NO: 1 as 16S rDNA, comprising the nucleotide sequence of SEQ ID NO: 2 as 16S rDNA
  • it provides a composition for the prevention, improvement or treatment of obesity or obesity-related diseases comprising an extract thereof as an active ingredient.
  • the composition for preventing, ameliorating or treating the obesity or obesity-related disease is preferably a pharmaceutical composition or a food composition.
  • the Lactobacillus brevis ( Lactobacillus brevis ) is preferably Lactobacillus brevis ( Lactobacillus brevis ) OK56 (Accession Number: KCCM 11516P).
  • the Lactobacillus sakei ( Lactobacillus sakei ) is preferably Lactobacillus sakei ( Lactobacillus sakei ) OK101 (Accession Number: KCCM 11664P).
  • the Lactobacillus plantarum ( Lactobacillus plantarum ) is preferably Lactobacillus plantarum OK169 (Accession Number: KCCM 11663P).
  • Lactobacillus brevis comprising at least one selected from the group consisting of soybean, deodeok, ginseng and cornus seed with the base sequence of SEQ ID NO: 1 as 16S rDNA ( Lactobacillus brevis ), Lactobacillus sakei comprising the nucleotide sequence of SEQ ID NO: 2 as 16S rDNA and Lactobacillus plantarum comprising the nucleotide sequence of SEQ ID NO: 4 as 16S rDNA It provides a composition for the prevention, improvement or treatment of obesity or obesity-related diseases comprising a fermentation product obtained by fermenting with one or more Lactobacillus lactic acid bacteria selected from the group consisting of or extract of the fermentation as an active ingredient.
  • the composition for preventing, ameliorating or treating the obesity or obesity-related disease is preferably a pharmaceutical composition or a food composition.
  • the Lactobacillus brevis ( Lactobacillus brevis ) is preferably Lactobacillus brevis ( Lactobacillus brevis ) OK56 (Accession Number: KCCM 11516P).
  • the Lactobacillus sakei ( Lactobacillus sakei ) is preferably Lactobacillus sakei ( Lactobacillus sakei ) OK101 (Accession Number: KCCM 11664P).
  • the Lactobacillus plantarum ( Lactobacillus plantarum ) is preferably Lactobacillus plantarum OK169 (Accession Number: KCCM 11663P).
  • Specific Bacillus strain according to the present invention is isolated from kimchi has a high safety, and has various functions such as excellent anti-obesity activity, blood cholesterol lowering activity, blood triglyceride lowering activity or antioxidant activity. Therefore, certain Bacillus strains according to the present invention can be used as a food and pharmaceutical material useful for preventing, ameliorating or treating diseases such as obesity, fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, arteriosclerosis and lipid-related metabolic syndrome have.
  • the product or extract thereof fermented soybean, deodeok, ginseng and cornus seed as a specific Bacillus strain according to the present invention can also be used as a food and pharmaceutical material useful for preventing, improving or treating obesity or obesity-related diseases.
  • 1 is a graph showing the effect of lactic acid bacteria on the differentiation inhibition of 3T3-L1 precursor adipocytes into adipocytes.
  • Figure 2 is a graph showing the antioxidant efficacy of the lactic acid bacteria at 50% inhibitory concentration (50% Scavenging Concentration).
  • culture means a product obtained by culturing a microorganism in a known liquid medium or a solid medium, and is a concept in which a microorganism is included.
  • pharmaceutically acceptable and “food acceptable” means that they do not significantly stimulate the organism and do not inhibit the biological activity and properties of the administered active substance.
  • prevention refers to any action that inhibits the symptoms or delays the progression of a particular disease (eg colitis) by administration of a composition of the invention.
  • treatment refers to any action that improves or beneficially alters the symptoms of a particular disease (eg, colitis) by administration of a composition of the present invention.
  • improvement refers to any action that at least reduces the parameters associated with the condition being treated, for example, the extent of symptoms.
  • the term "administration" means providing a subject with a composition of the present invention in any suitable manner.
  • the subject refers to all animals, such as humans, monkeys, dogs, goats, pigs or mice having a disease that can improve the symptoms of a particular disease by administering the composition of the present invention.
  • the term "pharmaceutically effective amount” refers to an amount sufficient to treat a disease at a reasonable benefit or risk ratio applicable to medical treatment, which refers to the type of disease, the severity, the activity of the drug, the drug, and the like. Sensitivity, time of administration, route of administration and rate of excretion, duration of treatment, factors including drug used concurrently, and other factors well known in the medical arts.
  • the novel lactic acid bacterium having various functionalities such as anti-obesity activity, blood cholesterol lowering activity, blood triglyceride lowering activity or antioxidant activity.
  • the novel lactic acid bacterium according to the present invention is Lactobacillus brevis comprising the nucleotide sequence of SEQ ID NO: 1 as 16S rDNA, Lactobacillus sakei comprising the nucleotide sequence of SEQ ID NO: 2 as 16S rDNA, and At least one Lactobacillus genus strain selected from the group consisting of Lactobacillus plantarum comprising the nucleotide sequence of SEQ ID NO: 4 as 16S rDNA.
  • Lactobacillus brevis is a bacillus that shows positive upon gram staining, glucose (Glucose), Amigdalin (Amygdalin), Arabinos (Arabinose), Esculin, Fructose, Galactose, Lactose, Mannose, Mannose, Raffinose, Rhamnose, Sorbitol, Sobitol, Sucrose, and Xylose are used. Lactobacillus brevis OK56 with accession number KCCM 11516P.
  • Lactobacillus sakei is a bacillus that shows positive upon gram staining, glucose (Glucose), Amigdalin (Amygdalin), Arabinos (Arabinose), Esculin, Fructose as a carbon source , Using galactose, glycerol, lactose, lactose, mannose, melibiose, raffinos, sorbitol, sucrose and xylose It is characterized in that, preferably Lactobacillus sakei OK101 with accession number KCCM 11664P.
  • Lactobacillus plantarum is a bacilli that show positive gram staining, and as a carbon source glucose (Glucose), Amigdalin (Amygdalin), Arabinos (Arabinose), Esculin (Fructose) ), Galactose, Glycerol, Lactose, Mannose, Melezitose, Meliviose, Raffinose, Rhamnose, Sorbitol It is characterized by using sucrose (Sucrose) and xylose (Xylose), preferably the accession number KCCM 11663P is Lactobacillus plantarum OK169.
  • novel lactic acid bacterium according to the present invention is Lactobacillus sakei OK156 comprising the nucleotide sequence of SEQ ID NO: 3 as 16S rDNA or Lactobacillus plantarum comprising the nucleotide sequence of SEQ ID NO: 5 as 16S rDNA.
  • Lactobacillus plantarum may further include.
  • the Lactobacillus sakei OK156 is a bacillus that shows positive gram staining, and as a carbon source, glucose (Glucose), amigdalin (Amygdalin), Arabinos (Arabinose), Esculin, Fructose, Galactose (Galactose), Glycerol (Glycerol), Lactose, (Lactose), Mannose (Mannose), Melibiose (Melibiose), Raffinose (Sorbitol) and sucrose (Sucrose) is characterized by using.
  • Lactobacillus plantarum OK215 is a bacilli that show positive gram staining, and as a carbon source, glucose (Glucose), amygdalin (Amygdalin), arabinose (Esculin), fructose ( Fructose, Galactose, Lactose, Lactose, Mannose, Melezitose, Melibiose, Raffinose, Rhamnose, Sorbitol, and Sucrose It is characterized by using).
  • the Lactobacillus strain of the present invention is preferably isolated from kimchi, such as cabbage kimchi or gad kimchi.
  • the present invention prevents or improves obesity or obesity-related diseases comprising lactic acid bacteria, cultures thereof, lysates or extracts thereof, as one of the above-described Lactobacillus strains, as an active ingredient. Or a therapeutic composition.
  • the culture of the lactic acid bacteria is a product obtained by culturing in Lactobacillus medium, the medium may be selected from known liquid medium or solid medium, for example, may be MRS liquid medium, MRS agar medium.
  • the present invention is a fermentation product obtained by fermenting at least one selected from the group consisting of soybean, deodeok, ginseng and cornus seed as a lactic acid bacterium consisting of at least one strain of Lactobacillus sp. It provides a composition for the prevention, improvement or treatment of obesity or obesity-related diseases comprising the extract of the fermentation as an active ingredient. Extracts of the fermentation may be prepared by various methods. For example, a method for obtaining an extract from a product obtained by fermenting a material selected from soybean, deodeok, ginseng and cornus seed with the novel lactic acid bacteria of the present invention, or an extract of a material selected from soybean, deodeok, ginseng and cornus seed.
  • Extractive solvents that may be used when preparing extracts of fermentation using solvent extraction are water, lower alcohols having 1 to 4 carbon atoms (e.g., methanol, ethanol, propanol and butanol) or hydrous lower alcohols which are mixtures thereof, Propylene glycol, 1,3-butylene glycol, glycerin, acetone, diethyl ether, ethyl acetate, butyl acetate, dichloromethane, chloroform, hexane and mixtures thereof, and may be selected from the group consisting of double water, alcohol or It is preferred to be selected from mixtures of.
  • lower alcohols having 1 to 4 carbon atoms e.g., methanol, ethanol, propanol and butanol
  • hydrous lower alcohols which are mixtures thereof
  • the water is preferably hot water.
  • the alcohol is preferably a lower alcohol having 1 to 4 carbon atoms, and the lower alcohol is more preferably selected from methanol or ethanol.
  • the alcohol content is preferably 50 ⁇ 90%.
  • extraction by supercritical fluid extraction using carbon dioxide extraction by ultrasound, separation using ultrafiltration membranes with constant molecular weight cut-off values, or various chromatography (size, charge, Active fractions obtained through various purification and extraction methods additionally carried out, such as separation by hydrophobicity or affinity), are also included in the extract of the present invention.
  • supercritical fluids have the properties of liquids and gases when the gas reaches a critical point at high temperature and high pressure, and have a chemically similar polarity to nonpolar solvents. J. Chromatogr. A. 1998; 479: 200-205.
  • supercritical carbon dioxide passes through an extraction vessel containing a certain amount of sample, the fat-soluble substance contained in the sample is extracted from the supercritical carbon dioxide.
  • the supercritical carbon dioxide containing a small amount of cosolvent is passed through the sample remaining in the extraction container to extract components that were not extracted with pure supercritical carbon dioxide alone.
  • the supercritical fluid used in the supercritical extraction method of the present invention can effectively extract the active ingredient by using supercritical carbon dioxide or a mixed fluid in which a co-solvent is added to carbon dioxide.
  • cosolvent one or a mixture of two or more selected from the group consisting of chloroform, ethanol, methanol, water, ethyl acetate, hexane and diethyl ether can be used. Most of the extracted samples contain carbon dioxide, which is volatilized into the air at room temperature, and the cosolvent can be removed by a reduced pressure evaporator.
  • the ultrasonic extraction method is an extraction method using the energy generated by the ultrasonic vibration, the ultrasonic wave can destroy the insoluble solvent contained in the sample in the water-soluble solvent, due to the high local temperature is generated Since the kinetic energy of the reactant particles is increased, sufficient energy required for the reaction is obtained, and the extraction efficiency is increased by inducing high pressure by the impact effect of ultrasonic energy to increase the mixing effect of the substance and the solvent contained in the sample.
  • the extraction solvent that can be used in the ultrasonic extraction method may be used one or a mixture of two or more selected from the group consisting of chloroform, ethanol, methanol, water, ethyl acetate, hexane and diethyl ether.
  • the extracted sample is vacuum filtered to recover the filtrate, and then removed by a vacuum evaporator, the extract can be obtained through a conventional extract preparation method of freeze drying.
  • the fermented product fermented with a specific Lactobacillus strain or a specific Lactobacillus strain of the present invention has various functionalities such as anti-obesity activity, blood cholesterol lowering activity, blood triglyceride lowering activity, etc., thus preventing or improving obesity or obesity-related diseases. Or as an active ingredient for treatment.
  • the obesity-related diseases are not limited in kind as long as they are caused by obesity or have a high correlation with obesity, for example, fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, arteriosclerosis, and lipid-related metabolic syndrome. It can be any one.
  • the lipid-related metabolic syndrome refers to a disease in which various metabolic diseases, such as diabetes and obesity, appear simultaneously in one person.
  • composition for preventing, ameliorating or treating obesity or obesity-related diseases of the present invention may be embodied as a pharmaceutical composition, a food additive, a food composition (particularly a functional food composition), a feed additive, or the like, depending on the purpose or aspect of use.
  • the content of the fermentation product fermented with a specific Lactobacillus strain or a specific Lactobacillus strain, which is an active ingredient in the composition may also be adjusted in various ranges according to the specific form of the composition, purpose of use, and aspects.
  • New lactic acid bacteria, cultures thereof, lysates thereof or extracts thereof as an active ingredient in the pharmaceutical composition for the prevention or treatment of obesity or obesity-related diseases according to the present invention is not particularly limited, for example 0.01 ⁇ based on the total weight of the composition 99% by weight, preferably 0.5-50% by weight, more preferably 1-30% by weight.
  • the pharmaceutical composition according to the present invention may further include an additive such as a pharmaceutically acceptable carrier, excipient or diluent in addition to the active ingredient.
  • Carriers, excipients and diluents that may be included in the pharmaceutical compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • the pharmaceutical composition for the prevention or treatment of obesity or obesity-related diseases of the present invention is a novel lactic acid bacteria, its culture, its lysate or extract thereof; Or a known active ingredient having a prophylactic or therapeutic effect of obesity or obesity-related diseases in addition to fermentation products or extracts thereof obtained by fermenting at least one selected from the group consisting of soybean, deodeok, ginseng and cornus seed with new lactic acid bacteria. It may contain more than one species.
  • the pharmaceutical composition of the present invention may be formulated into a formulation for oral administration or a parenteral administration by a conventional method, and when formulated, such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations contain at least one excipient such as starch, calcium carbonate, sucrose in active ingredients. ), Lactose (Lactose) or gelatin can be prepared by mixing. In addition to simple excipients, lubricants such as magnesium styrate talc may also be used.
  • Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents, water and liquid paraffin. have.
  • Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • the pharmaceutical composition of the present invention can be administered orally or parenterally to mammals including humans according to a desired method, and parenteral administration methods include external skin, intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, muscle Intra-injection or intrathoracic injection;
  • the dosage of the pharmaceutical composition of the present invention is not particularly limited as long as it is a pharmaceutically effective amount, and the range thereof depends on the weight, age, sex, health condition, diet, time of administration, method of administration, excretion rate and severity of the disease. Varies.
  • Typical daily dosages of the pharmaceutical compositions of the present invention are not particularly limited but are preferably 0.1 to 3000 mg / kg, more preferably 1 to 2000 mg / kg, once daily based on the active ingredient. Or divided into several doses.
  • novel lactic acid bacteria, its culture, its lysate or extract thereof as an active ingredient in a food composition for preventing or improving obesity or obesity-related diseases of the present invention
  • a fermentation product or extract thereof obtained by fermenting at least one selected from the group consisting of soybean, deodeok, ginseng and cornus seed with new lactic acid bacteria, based on the total weight of the composition, preferably 0.01 to 50% by weight, preferably 0.1 25 wt%, more preferably 0.5-10 wt%, but is not limited thereto.
  • the food composition of the present invention includes the form of pills, powders, granules, acupuncture, tablets, capsules, or liquids, and examples of specific foods include meat, sausage, bread, chocolate, candy, snacks, confectionary, pizza, ramen, Other noodles, gums, dairy products, including ice cream, various soups, beverages, tea, functional water, drinks, alcoholic beverages and vitamin complexes, and includes all of the health food in the usual sense.
  • the food composition of the present invention may contain various flavors or natural carbohydrates as additional ingredients.
  • the food composition of the present invention is a variety of nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols And carbonation agents used in carbonated beverages.
  • the food composition of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage. These components can be used independently or in combination.
  • the above-mentioned natural carbohydrates are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol and erythritol.
  • natural flavoring agents such as taumartin, stevia extract, synthetic flavoring agents such as saccharin, aspartame, etc. may be used.
  • GAM liquid medium GAM broth; Nissui Pharmaceutical, Japan. Then, the supernatant was taken, transplanted into BL agar medium (Nissui Pharmaceutical, Japan), and anaerobicly cultured at 37 ° C. for about 48 hours, and then colonies were formed.
  • Table 1 shows the control numbers and strain names of lactic acid bacteria isolated from Chinese cabbage kimchi and gad kimchi
  • Table 2 shows the control numbers and strain names of lactic acid bacteria isolated from human feces.
  • Control Number Strain name Control Number Strain name One Leuconostoc mesenteroides C1 17 Lactobacillus pentosus C15 2 Leuconostoc mesenteroides C2 18 Lactobacillus pentosus C27 3 Lactobacillus mesenteroides OK2 19 Lactobacillus sakei C14 4 Lactobacillus curvatus C3 20 Lactobacillus sakei C21 5 Lactobacillus brevis C4 21 Lactobacillus sakei C22 6 Lactobacillus brevis C5 22 Lactobacillus sakei C23 7 Lactobacillus brevis OK55 23 Lactobacillus sakei OK101 8 Lactobacillus brevis OK56 24 Lactobacillus sakei OK156 9 Lactobacillus acidophilus C9 25 Lactobacillus plantarum C12 10 Lactobacillus acidophilus C20 26 Lactobacillus plantarum C24 11 Lactobacillus acidophilus OK75 27 Lactobac
  • Lactobacillus brevis OK56 Lactobacillus sakei OK101, Lactobacillus sakei OK156, Lactobacillus plantarum OK169 And Lactobacillus plantarum OK215 physiological characteristics and chemical classification characteristics are shown in Table 3.
  • 16S rDNA nucleotide sequence of each strain was identified by BLAST search in Genebank (http://www.ncbi.nlm.nih.gov/). As a result, Lactobacillus brevis OK56 16S rDNA (see SEQ ID NO: 1) was identified. Lactobacillus brevis ATCC 367 (NCBI ACCESSION: NR_075024) showed 99% homology with Lactobacillus sakei OK101 16S rDNA (see SEQ ID NO: 2).
  • Lactobacillus sakei NBRC 15893 (NCBI ACCESSION: NR_113821) showed 98% homology with the 16S rDNA subsequence, and Lactobacillus sakei OK156 16S rDNA (see SEQ ID NO: 3) was ( Lactobacillus sakei ) 100% homology with 16S rDNA subsequence of NBRC 15893 (NCBI ACCESSION: NR_113821), and 16S rDNA of Lactobacillus plantarum OK169 (see SEQ ID NO: 4) Room ( Lactobacillus plantarum ) 97% homology with the 16S rDNA subsequence of CIP 103151 (NCBI ACCESSION: NR_104573), and the 16S rDNA of Lactobacillus plantarum OK215 (see SEQ ID NO: 5) is shown in Lactobacillus plantarum (see SEQ ID NO: 5). Lactobacillus plantarum ) showed 99% homology
  • Mouse preadipocytes 3T3-L1 were dispensed into 12 well plates at a concentration of 2 ⁇ 10 4 / mL and cultured at 37 ° C. and 5% CO 2 . At this time, use 3T3-L1 complete media [DMEM / high glucose (Thermo scientific, USA), newborn calf serum (Thermo scientific), 1% penicillin-streptomycin solution (Thermo scientific)] until the 100% confluency point as a medium. It was. At the 100% confluency time point, it was maintained for two more days.
  • Progenitor cells were then incubated with MDI media (DMEM / high glucose, 10% fetal bovine serum, 1% penicillin-streptomycin solution, 0.5 mM 3-isobutyl-1-methylxanthine, 1 uM dexamethazone, 5 ⁇ g / ml insulin) for 2 days.
  • MDI media DMEM / high glucose, 10% fetal bovine serum, 1% penicillin-streptomycin solution, 0.5 mM 3-isobutyl-1-methylxanthine, 1 uM dexamethazone, 5 ⁇ g / ml insulin
  • Differentiation into adipocytes was induced for 2 days, and differentiation media (DMEM / high glucose, 10% fetal bovine serum, 1% penicillin-streptomycin solution, 5 ⁇ g / ml insulin) with lactic acid bacteria 2 days after induction of differentiation. ) was added and incubated for 2 days.
  • the lactic acid bacteria were added by suspension in phosphate buffered saline (PBS), the amount was 1 ⁇ 10 4 CFU / well. After that, the cells were replaced with growth media (DMEM / high glucose, 10% fetal bovine serum, 1% penicillin-streptomycin solution) every 4 days to complete the differentiation of adipocytes.
  • PBS phosphate buffered saline
  • the proliferative cell cultures were washed three times with PBS to remove the cultures and treated with 10% formalin for 1 hour to fix the cells. Subsequently, the cells were treated with oil red O solution in the dark for 30 minutes and washed with distilled water to stain the fat globules. Thereafter, isopropanol was added to dissolve the aliphatic sample stained with an oil red O solution, and the absorbance was measured at 520 nm using a Spectrophotometer. The inhibition rate of adipocyte differentiation of each lactic acid bacterium was calculated by the following equation.
  • Control O.D. is the absorbance of the test solution to which ethanol was added instead of the sample
  • Sample O.D. is the absorbance of the test solution to which the sample was added.
  • Lactobacillus brevis (Lactobacillus brevis), as also seen in the first eruption was inhibitory ability is best for OK56, followed by Lactobacillus Planta Room (Lactobacillus plantarum) OK169, Lactobacillus four K (Lactobacillus sakei) OK101, Lactobacillus Planta Lactobacillus plantarum OK215 and Lactobacillus sakei OK156.
  • the lactic acid bacteria were suspended in 10 mM phosphate buffered saline (PBS) to prepare samples having lactic acid bacteria concentrations of 10, 1, 0.1 and 0.01 mg / ml, respectively, and the same amount of 0.1 mM DPPH solution (2,2). 39.4 mg of -diphenyl-1-picrylhydrazyl was dissolved in ethanol to prepare 1000 ml), and then stirred for 10 seconds and reacted at 37 ° C. for 30 minutes. The reaction was then measured at 515 nm using a Spectrophotometer. On the other hand, a test solution in which ethanol was added instead of the sample was used as a control. In addition, Vitamin C was used as a reference for comparing the antioxidant efficacy. Inhibition rate of each lactic acid bacteria was calculated by the following equation.
  • Control O.D. is the absorbance of the control in which ethanol was added instead of the sample
  • Sample O.D. is the absorbance of the test solution in which the sample was added.
  • FIG. 2 is a graph showing the antioxidant efficacy of the lactic acid bacteria at 50% inhibitory concentration (50% Scavenging Concentration).
  • 50% Scavenging Concentration refers to the concentration of lactic acid bacteria in the sample required to reduce the absorbance of the control to 1/2, that is, the concentration of lactic acid bacteria in the sample with 50% inhibition rate. This means that the antioxidant effect is great. As shown in FIG.
  • the anti-oxidant effect was the best Lactobacillus brevis ( Lactobacillus brevis ) OK56 as well as the anti-obesity effect, followed by the Lactobacillus plantarum OK169, Lactobacillus sakei ( Lactobacillus sakei ) OK101 , Lactobacillus plantarum OK215 and Lactobacillus sakei OK156.
  • a high fat diet D12451, Research Diets, New Brunswick, NJ
  • the obese high fat diet group was divided into six groups of 6 animals (HF, HF + OK56, HF + OK169, HF + OK101, HF + OK215, HF + OK156), and then the HF group was fed a high fat diet.
  • phosphate buffered saline (PBS) was orally administered for 5 weeks, and HF + OK56, HF + OK169, HF + OK101, HF + OK215, and HF + OK156 groups were fed a high-fat diet.
  • Other lactic acid bacteria were suspended in phosphate buffered saline (PBS) and orally administered for 5 weeks.
  • the normal diet group was fed orally administered the same amount of phosphate buffered saline (PBS) for 5 weeks at the same time as the normal diet.
  • the group of oral administration of lactic acid bacteria with high fat diet after induction of obesity showed a lower weight of adipose tissue when compared to the group receiving only high fat diet after induction of obesity.
  • Plasma trigiyceride, plasma cholesterol, and plasma HDL cholesterol levels of the experimental animals that induced obesity and received lactic acid bacteria for 5 weeks were measured as follows.
  • Plasma neutral lipids were measured using a kit for measuring neutral lipids (ASAN PHARM. CO. LTD, South Korea). 1.5 ml of enzyme solution and 10 ⁇ l of plasma were added to the test tube, followed by stirring. Thereafter, the sample was warmed for 10 minutes in a water bath at 37 ° C. with a standard solution having a neutral lipid content of 0, 75, 150, 225, 300 mg / dL, and the absorbance at 550 nm was measured for colorimetric determination. It was. In addition, plasma total cholesterol was measured using a total cholesterol measurement kit (ASAN PHARM. CO. LTD, South Korea). 1.5 ml of enzyme solution and 10 ⁇ l of plasma were added to the test tube, followed by stirring.
  • the sample was warmed for 10 minutes in a water bath at 37 ° C. with a standard solution having a total cholesterol content of 0, 75, 150, 225, 300 mg / dL, and the absorbance at 500 nm was measured and colorimetrically determined.
  • plasma HDL cholesterol was measured using a kit for measuring HDL cholesterol (ASAN PHARM. CO. LTD, South Korea). 50 ⁇ l of the needle was added to 50 ⁇ l of plasma, stirred, and allowed to stand at room temperature for 10 minutes, followed by centrifugation at 3000 rpm for 10 minutes to obtain 25 ⁇ l of supernatant. Thereafter, 750 ⁇ l of the enzyme solution was added to the supernatant and stirred.
  • the sample was then warmed for 5 minutes in a water bath at 37 ° C. with a standard solution having an HDL cholesterol content of 0, 10, 20, 30, 40 and 50 mg / dl, respectively, and the absorbance at 500 nm was measured. Colorimetric quantification was carried out.
  • Table 6 shows the results of the measurement of plasma total triglyceride, total cholesterol and HDL cholesterol content for each experimental group.
  • Lactobacillus brevis OK56 was inoculated in 10 ml of MRS broth (Difco, USA) and incubated for about 24 hours. Thereafter, the Lactobacillus brevis OK56 culture was centrifuged to remove the medium and cells were obtained. Thereafter, 10 g of skim soybean powder was suspended in 90 ml of water and sterilized, and the cells were inoculated to a concentration of 1 ⁇ 10 9 / ml and incubated for about 3 days. Thereafter, the mixed culture of soybean and lactic acid bacteria was lyophilized to obtain lactic acid bacteria fermented soybean powder.
  • Lactobacillus brevis OK56 was inoculated in 10 ml of MRS broth (Difco, USA) and incubated for about 24 hours. Thereafter, the Lactobacillus brevis OK56 culture was centrifuged to remove the medium and cells were obtained. Thereafter, 10 g of Deodeok powder was suspended in 90 ml of water and sterilized, and the cells were inoculated to a concentration of 1 ⁇ 10 9 / ml and incubated for about 3 days. Thereafter, the mixed culture solution of Deodeok and lactic acid bacteria was lyophilized to obtain lactic acid bacteria fermentation deodeok powder. In addition, 2 times the volume of ethanol was added to the mixed culture of Deodeok and lactic acid bacteria, followed by extraction. The extract was concentrated under reduced pressure and lyophilized to obtain an extract of Lactobacillus fermented Deodeok.
  • Lactobacillus brevis OK56 was inoculated in 10 ml of MRS broth (Difco, USA) and incubated for about 24 hours. Thereafter, the Lactobacillus brevis OK56 culture was centrifuged to remove the medium and cells were obtained. Thereafter, 10 g of ginseng powder was suspended in 90 ml of water and sterilized, and the cells were inoculated to a concentration of 1 ⁇ 10 9 / ml and incubated for about 3 days. Thereafter, the mixed culture of ginseng and lactic acid bacteria was lyophilized to obtain lactic acid bacteria fermented ginseng powder. In addition, two times the volume of ethanol was added to the mixed culture of ginseng and lactic acid bacteria to extract the extract, the extract was concentrated under reduced pressure and lyophilized to obtain an extract of lactic acid bacteria fermented ginseng.
  • Lactobacillus brevis OK56 was inoculated in 10 ml of MRS broth (Difco, USA) and incubated for about 24 hours. Thereafter, the Lactobacillus brevis OK56 culture was centrifuged to remove the medium and cells were obtained. Thereafter, 10 g of degreasing cornus seed powder was suspended and sterilized in 90 ml of water, and the cells were inoculated to a concentration of 1 ⁇ 10 9 / ml and incubated for about 3 days. Thereafter, the mixed culture solution of cornus seeds and lactic acid bacteria was lyophilized to obtain lactic acid bacteria fermented cornus seeds powder. In addition, two times the volume of ethanol was added to the mixed culture solution of cornus seeds and lactic acid bacteria, and the extract was concentrated under reduced pressure and lyophilized to obtain an extract of lactic acid bacteria fermented cornus oil.
  • a high fat diet D12451, Research Diets, New Brunswick, NJ
  • the obese high fat diet group was divided into five groups (HF, HF + SOK56, HF + COK56, HF + POK56, and HF + OOK56), each of which was fed a high-fat diet and phosphate buffered saline.
  • phosphate buffered saline, PBS phosphate buffered saline
  • HF + SOK56, HF + COK56, HF + POK56, and HF + OOK56 groups were fed high-fat diets, and at the same time, different fermenters or extracts thereof were phosphate buffered. It was suspended in saline (phosphate buffered saline (PBS) and administered orally for 5 weeks.
  • the normal diet group was fed orally administered the same amount of phosphate buffered saline (PBS) for 5 weeks at the same time as the normal diet.
  • the body weight and dietary intake of the test animals were measured at a constant time every day during the entire test period, and the results are shown in Table 7 below.
  • SF subcutaneous fat
  • EF epididymal fat
  • PF Peripheral fat
  • MF mesenteric fat
  • BAT brown adipose tissue
  • the group of oral administration of lactic acid bacteria fermented product or extract thereof with high fat diet after induction of obesity showed a lower weight of adipose tissue when compared to the group receiving only high fat diet after induction of obesity.
  • Lactobacillus brevis OK56 cultures were Lactobacillus sakei OK101, Lactobacillus sakei OK156, Lactobacillus plantarum OK169 and Lactobacillus plantarum OK169.
  • Cultures of lactic acid bacteria such as Planta room ( Lactobacillus plantarum OK215) or the like can be replaced with fermented products prepared by fermenting soybean, deodeok, ginseng, cornus seed and the like or extracts of the fermented products.
  • tablets were prepared by tableting according to a conventional method for producing tablets.
  • the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.
  • Lactobacillus brevis OK56 cultures were Lactobacillus sakei OK101, Lactobacillus sakei OK156, Lactobacillus plantarum OK169 and Lactobacillus plantarum OK169.
  • Cultures of lactic acid bacteria such as Planta room ( Lactobacillus plantarum OK215) or the like can be replaced with fermented products prepared by fermenting soybean, deodeok, ginseng, cornus seed and the like or extracts of the fermented products.
  • Brown rice, barley, glutinous rice, and yulmu were alphad by a known method, and then dried and roasted to prepare a powder having a particle size of 60 mesh.
  • Black beans, black sesame seeds, and perilla were also steamed and dried by a known method, and then ground to a powder having a particle size of 60 mesh.
  • the grains, seeds and the fermented deodeok extract of Preparation Example 2 prepared above were formulated in the following ratio.
  • Seeds (7 parts by weight perilla, 8 parts by weight black beans, 7 parts by weight black sesame seeds),
  • a homogeneous blend of subsidiary materials such as liquid fructose (0.5 g), oligosaccharide (4 g), sugar (2 g), salt (0.5 g) and water (77 g) and 1 g of fermented deodeok extract of Preparation Example 2 After sterilization, it was prepared by packing it in a small packaging container such as a glass bottle or a plastic bottle.
  • the inventors of the present invention patented the Lactobacillus brevis OK56 on February 5, 2014 to the Korea Microorganism Conservation Center, an official depository, and received the accession number of KCCM 11516P.
  • the inventors of the present invention secured the Lactobacillus sakei OK101 to the Korea Microorganism Conservation Center, an official depository institution on February 5, 2014, and received the accession number of KCCM 80070, and on January 28, 2015. Changed to patent deposit and received the accession number of KCCM 11664P.
  • the inventors of the present invention secured the Lactobacillus plantarum OK169 to the Korea Microorganism Conservation Center, an authorized depository institution on February 5, 2014, and received the accession number of KCCM 80069, January 28, 2015. Changed to a patent deposit on the date was given an accession number of KCCM 11663P.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une nouvelle souche de Lactobacillus isolée à partir du kimchi. Une souche de Bacillus spécifique selon la présente invention est isolée à partir de kimchi, et présente diverses fonctionnalités, telles qu'une excellente activité contre l'obésité, pour la réduction du cholestérol dans le sang et des triglycérides dans le sang, ou une excellente activité antioxydante. C'est pourquoi la souche de Bacillus spécifique de l'invention peut être utilisée en tant qu'aliment et médicament utile pour prévenir, soulager, ou traiter des maladies telles que l'obésité, la stéatose hépatique, le diabète de type 2, l'hyperlipidémie, les maladies cardiovasculaires, l'athérosclérose, et le syndrome métabolique liés aux lipides. En outre, un produit obtenu par la fermentation de graines de soja, de Codonopsis lanceolata, de ginseng, et de Cornus officinalis avec la souche de Bacillus spécifique de la présente invention, ou son extrait, peut également être utilisé en tant qu'aliment et médicament utiles pour prévenir, soulager, ou traiter l'obésité ou les maladies liées à l'obésité.
PCT/KR2015/001480 2014-02-17 2015-02-13 Nouvelles bactéries d'acide lactique possédant un effet inhibiteur sur l'obésité et leur utilisation WO2015122717A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2014-0018105 2014-02-17
KR20140018105 2014-02-17

Publications (1)

Publication Number Publication Date
WO2015122717A1 true WO2015122717A1 (fr) 2015-08-20

Family

ID=53800385

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/001480 WO2015122717A1 (fr) 2014-02-17 2015-02-13 Nouvelles bactéries d'acide lactique possédant un effet inhibiteur sur l'obésité et leur utilisation

Country Status (2)

Country Link
KR (3) KR101740583B1 (fr)
WO (1) WO2015122717A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180036592A (ko) * 2016-09-30 2018-04-09 씨제이제일제당 (주) 신규한 락토바실러스 사케이 및 이를 포함하는 조성물
EP3345993A4 (fr) * 2015-09-03 2019-03-06 CJ Cheiljedang Corporation Nouvelle souche isolée a partir de meju traditionnel, procédé de préparation de koji de soja l'utilisant, et koji de soja préparé par ledit procédé de préparation
KR20190068075A (ko) * 2017-12-08 2019-06-18 한국식품연구원 비만 억제 활성을 갖는 락토바실러스 펜토수스 ao21-1 균주 및 이를 포함하는 비만 개선 또는 치료용 조성물
CN110494551A (zh) * 2017-01-31 2019-11-22 庆熙大学校产学协力团 新型乳酸菌及其用途
CN113444669A (zh) * 2021-07-27 2021-09-28 中国海洋大学 一株植物乳杆菌Lactobacillus plantarum F3-2及其应用
US11554146B2 (en) 2017-11-02 2023-01-17 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria and use thereof
US11771725B2 (en) 2015-09-15 2023-10-03 University-Industry Cooperation Group Of Kyung Hee University Lactobacillus having various functions, and use thereof

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101937364B1 (ko) * 2016-01-28 2019-01-11 경희대학교 산학협력단 면역조절 작용을 가는 사람 소화관 유래 신규 유산균 및 이의 용도
US20210187044A1 (en) * 2016-05-24 2021-06-24 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of controlling blood sugar and use thereof
KR101670048B1 (ko) * 2016-07-26 2016-10-27 (주)메디톡스 개체의 지방 함량을 감소시키는 미생물 및 그의 용도
KR101679045B1 (ko) * 2016-10-14 2016-11-23 (주)메디톡스 개체의 지방 함량을 감소시키는 미생물 및 그의 용도
KR101873239B1 (ko) * 2017-10-13 2018-07-04 주식회사 지놈앤컴퍼니 락토바실러스 파라카제이 lm1010 균주 및 이를 포함하는 비만 또는 당뇨병 예방 및 치료용 조성물
KR20190043885A (ko) * 2017-10-19 2019-04-29 주식회사 프로바이오닉 락토바실러스 사케이 Probio-65 또는 그의 추출물을 포함하는 당뇨병의 예방 또는 치료용 조성물
KR102151011B1 (ko) * 2017-10-25 2020-09-02 경상대학교산학협력단 숙성새싹삼 추출물의 발효물을 유효성분으로 함유하는 간질환의 예방, 개선 또는 치료용 조성물
KR101938801B1 (ko) 2017-11-20 2019-01-15 한국식품연구원 항산화 및 항노화 효과를 갖는 락토바실러스 사케이 WiKim0066
KR102039229B1 (ko) 2017-12-07 2019-10-31 재단법인 포항테크노파크 비만, 당뇨와 지방간의 예방과 치료 효과를 갖는 바실러스 혼합 조성물 및 이의 용도
KR101997362B1 (ko) 2017-12-08 2019-07-08 비거트유산균 주식회사 락토바실러스 플란타룸 bk-021 균주 또는 이를 함유하는 항비만용 조성물
KR102011882B1 (ko) * 2017-12-26 2019-08-20 주식회사 종근당바이오 항비만 효과를 갖는 락토바실러스 플란타룸 k50 균주 및 이의 용도
KR102011881B1 (ko) * 2017-12-26 2019-08-20 주식회사 종근당바이오 항비만 효과를 갖는 락토바실러스 플란타룸 k10 균주 및 이의 용도
KR102011883B1 (ko) * 2017-12-26 2019-08-20 주식회사 종근당바이오 항비만 효과를 갖는 락토바실러스 플란타룸 kc3 균주 및 이의 용도
US11484557B2 (en) 2018-08-31 2022-11-01 Mediogen Co., Ltd. Human-derived Lactobacillus fermentum MG4231 or Lactobacillus fermentum MG4244 strain having anti-obesity activity, and composition comprising same
KR102183841B1 (ko) * 2018-10-08 2020-11-27 건국대학교 산학협력단 신규한 락토바실러스 플란타룸 Ln4 균주 및 이를 포함하는 비만의 예방 및 치료용 약학적 조성물
KR102190239B1 (ko) * 2018-10-08 2020-12-11 건국대학교 산학협력단 신규한 락토바실러스 플란타룸 Lb41 균주 및 이를 포함하는 비만의 예방 및 치료용 약학적 조성물
KR20200076001A (ko) * 2018-12-18 2020-06-29 동화약품주식회사 체중 및 체지방 감소 효능을 갖는 신규 유산균 및 이의 용도
JP2022522151A (ja) * 2019-02-26 2022-04-14 インダストリー ファウンデーション オブ チョンナム ナショナル ユニバーシティー 新規なラクトバチルスサケイｃｖｌ－００１菌株又はその培養液を含む骨疾患又は代謝性疾患改善、予防又は治療用組成物
KR20210057266A (ko) 2019-11-11 2021-05-21 비거트유산균 주식회사 락토바실러스 플란타룸 bk-021 균주를 함유하는 알파-글루코시다아제 억제용 또는 항비만용 조성물
CA3164465A1 (fr) * 2019-12-31 2021-07-08 Gi Biome Souche de lactobacillus plantarum, et composition pour la prevention ou le traitement des maladies metaboliques la contenant
KR102179481B1 (ko) * 2020-01-16 2020-11-16 (주)메디톡스 개체의 지방 함량을 감소시키는 미생물, 이를 동정하기 위한 방법 및 키트
KR102274678B1 (ko) 2020-07-16 2021-07-12 (주)코엔바이오 신규한 락토바실러스 플란타룸 아종 플란타룸 Ｃｅｂ－ｋｃ－００７ 균주 및 이를 포함하는 항비만 효능을 가지는 조성물
KR102198827B1 (ko) * 2020-07-24 2021-01-05 주식회사 리부트라이프 신규 락토바실러스 플란타럼 균주 및 이를 포함하는 비만 예방 또는 치료용 조성물
US20240115632A1 (en) * 2021-02-04 2024-04-11 Neoregen Biotech Composition comprising lactobacillus plantarum-derived polysaccharide or extract
KR102294456B1 (ko) 2021-02-17 2021-08-27 주식회사 메디오젠 영유아 유래 유산균 락토바실러스 람노서스 mg4502 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물
KR102294445B1 (ko) 2021-02-17 2021-08-27 주식회사 메디오젠 영유아 유래 유산균 락토바실러스 파라카제이 mg4592 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물
KR102294451B1 (ko) 2021-02-17 2021-08-27 주식회사 메디오젠 영유아 유래 유산균 락토바실러스 아시도필러스　mg4558 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물
CN113249249A (zh) * 2021-04-29 2021-08-13 南昌大学 一种具有缓解动脉粥样硬化功效的植物乳杆菌zdy04
KR102454241B1 (ko) * 2021-05-26 2022-10-14 롯데칠성음료주식회사 체지방 감소 효과를 가지는 락토바실러스 플랜타럼 균주 lrcc5282 및 이의 용도
AU2022302837A1 (en) * 2021-06-30 2023-07-06 Gi Biome Inc. Composition comprising three lactobacillus sp. strains, and use thereof
KR102639561B1 (ko) * 2022-05-25 2024-02-26 전남대학교 산학협력단 락토바실러스 플란타룸 nchbl-004 균주 또는 이의 배양액을 이용한 비만, 당뇨 또는 지방간을 포함하는 대사성 질환 예방, 치료 또는 개선용 조성물
KR102506366B1 (ko) * 2022-08-16 2023-03-09 (주)지에이치바이오 락토바실러스 플란타럼 ku15120 균주 또는 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080029989A (ko) * 2008-02-22 2008-04-03 구안산업 주식회사 인삼 가공품을 포함하는 리파아제 억제제, 이를 포함하는기능성 식품 및 의약 조성물
WO2012050907A2 (fr) * 2010-09-28 2012-04-19 The Regents Of The University Of California Agonistes de gaba dans le traitement de troubles associés au syndrome métabolique et combinaisons de gaba dans le traitement ou la prophylaxie du diabète de type i
WO2012086909A2 (fr) * 2010-12-24 2012-06-28 한국화학연구원 Procédé de préparation d'acides gamma-aminobutyriques à partir de glutamate monosodique faisant appel à des souches de lactobacilles ou à des souches de lactobacilles recombinées
KR20130092182A (ko) * 2012-02-10 2013-08-20 매일유업주식회사 알코올 분해능이 우수한 락토바실러스 브레비스 및 그를 함유하는 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101494279B1 (ko) * 2010-10-01 2015-04-29 주식회사한국야쿠르트 지방세포 분화 유도에 관여하는 유전자의 발현을 억제함으로써 지방세포 분화 억제 효능을 갖는 락토바실러스 플란타룸 케이와이1032 및 이를 유효성분으로 함유하는 제품
BG66608B1 (bg) 2011-05-04 2017-10-16 "Ел Би Булгарикум" ЕАД Полибактериален пробиотичен препарат
KR101394348B1 (ko) * 2011-10-28 2014-05-13 대상에프앤에프 주식회사 대사질환 또는 염증질환 치료 및 예방 효과가 있는 락토바실러스 플란타륨 ｄｓｒ920 및 이의 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080029989A (ko) * 2008-02-22 2008-04-03 구안산업 주식회사 인삼 가공품을 포함하는 리파아제 억제제, 이를 포함하는기능성 식품 및 의약 조성물
WO2012050907A2 (fr) * 2010-09-28 2012-04-19 The Regents Of The University Of California Agonistes de gaba dans le traitement de troubles associés au syndrome métabolique et combinaisons de gaba dans le traitement ou la prophylaxie du diabète de type i
WO2012086909A2 (fr) * 2010-12-24 2012-06-28 한국화학연구원 Procédé de préparation d'acides gamma-aminobutyriques à partir de glutamate monosodique faisant appel à des souches de lactobacilles ou à des souches de lactobacilles recombinées
KR20130092182A (ko) * 2012-02-10 2013-08-20 매일유업주식회사 알코올 분해능이 우수한 락토바실러스 브레비스 및 그를 함유하는 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEO, M. J. ET AL.: "Expression and characterization of a glutamate decarboxylase from Lactobacillus brevis 877G producing y-aminobutyric acid", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, vol. 77, no. 4, 23 April 2013 (2013-04-23), pages 853 - 856, XP055219771 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10645962B2 (en) 2015-09-03 2020-05-12 Cj Cheiljedang Corporation Strain isolated from traditional meju, soybean koji preparation method using same, and soybean koji prepared by the same preparation method
EP3345993A4 (fr) * 2015-09-03 2019-03-06 CJ Cheiljedang Corporation Nouvelle souche isolée a partir de meju traditionnel, procédé de préparation de koji de soja l'utilisant, et koji de soja préparé par ledit procédé de préparation
US11700871B2 (en) 2015-09-03 2023-07-18 Cj Cheiljedang Corporation Strain isolated from traditional meju, soybean koji preparation method using same, and soybean koji prepared by the same preparation method
US11771725B2 (en) 2015-09-15 2023-10-03 University-Industry Cooperation Group Of Kyung Hee University Lactobacillus having various functions, and use thereof
CN110023487B (zh) * 2016-09-30 2023-04-18 Cj第一制糖株式会社 新型清酒乳杆菌和包含其的组合物
EP3521415A4 (fr) * 2016-09-30 2020-05-06 CJ Cheiljedang Corporation Nouveau lactobacillus sakei et composition le comprenant
CN110023487A (zh) * 2016-09-30 2019-07-16 Cj第一制糖株式会社 新型清酒乳杆菌和包含其的组合物
AU2017337936B2 (en) * 2016-09-30 2021-03-04 Cj Cheiljedang Corporation Novel Lactobacillus Sakei And Composition Comprising The Same
KR20180036592A (ko) * 2016-09-30 2018-04-09 씨제이제일제당 (주) 신규한 락토바실러스 사케이 및 이를 포함하는 조성물
KR101992537B1 (ko) 2016-09-30 2019-06-25 씨제이제일제당 (주) 신규한 락토바실러스 사케이 및 이를 포함하는 조성물
CN110494551A (zh) * 2017-01-31 2019-11-22 庆熙大学校产学协力团 新型乳酸菌及其用途
CN110494551B (zh) * 2017-01-31 2023-06-16 庆熙大学校产学协力团 新型乳酸菌及其用途
US11554146B2 (en) 2017-11-02 2023-01-17 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria and use thereof
KR102136718B1 (ko) 2017-12-08 2020-08-14 한국식품연구원 비만 억제 활성을 갖는 락토바실러스 펜토수스 ao21-1 균주 및 이를 포함하는 비만 개선 또는 치료용 조성물
KR20190068075A (ko) * 2017-12-08 2019-06-18 한국식품연구원 비만 억제 활성을 갖는 락토바실러스 펜토수스 ao21-1 균주 및 이를 포함하는 비만 개선 또는 치료용 조성물
CN113444669A (zh) * 2021-07-27 2021-09-28 中国海洋大学 一株植物乳杆菌Lactobacillus plantarum F3-2及其应用

Also Published As

Publication number Publication date
KR101740583B1 (ko) 2017-05-29
KR102121461B1 (ko) 2020-06-10
KR102121463B1 (ko) 2020-06-10
KR20160097183A (ko) 2016-08-17
KR20160098149A (ko) 2016-08-18
KR20150098202A (ko) 2015-08-27

Similar Documents

Publication Publication Date Title
WO2015122717A1 (fr) Nouvelles bactéries d'acide lactique possédant un effet inhibiteur sur l'obésité et leur utilisation
WO2017204374A1 (fr) Nouvelles bactéries lactiques capables de réguler la glycémie et leur utilisation
WO2016053003A1 (fr) Procédé pour la préparation d'une préparation microbienne dans lequel de l'aglycone s'accumule dans des cellules et préparation microbienne préparée par ce procédé
KR101981333B1 (ko) 항비만 활성을 갖는 인체 유래 락토바실러스 퍼멘툼 mg4231 또는 락토바실러스 퍼멘툼 mg4244 균주 및 이를 포함하는 조성물
EP3454869A1 (fr) Composition comprenant une bactérie lactique pour la prévention et le traitement de la vaginose et son utilisation
WO2019135637A1 (fr) Procédé de préparation d'un extrait de feuille de gynostemma pentaphyllum contenant une quantité accrue de saponine efficace de faible masse moléculaire et une quantité réduite de benzopyrène, et extrait de feuille de gynostemma pentaphyllum préparé selon ledit procédé
WO2017074037A1 (fr) Nouvelle souche dérivée d'aliments fermentés traditionnels et présentant une excellente productivité enzymatique, et procédé de préparation d'aliments fermentés enzymatiques à base de céréales à l'aide de ladite souche
KR101736033B1 (ko) 항비만 활성을 가지는 락토바실러스 사케아이
WO2021060945A1 (fr) Microbe intestinal humain anaérobie obligatoire pour le traitement du cancer, et son utilisation
WO2018093238A2 (fr) Composition comprenant en tant qu'ingrédient actif une souche présentant une excellente aptitude à produire de l'acide formique pour prévenir ou traiter l'obésité ou des syndromes métaboliques provoqués par l'obésité
WO2018062914A1 (fr) Nouveau lactobacillus sakei et composition le comprenant
WO2023055188A1 (fr) Nouveaux probiotiques et utilisation associée
WO2020130471A1 (fr) Nouveau lactobacillus ayant un effet de réduction du poids corporel ou de la graisse corporelle et son utilisation
WO2017131402A1 (fr) Nouvelle bactérie lactique dérivée d'intestin humain ayant une fonction immunorégulatrice, et son utilisation
WO2021066549A1 (fr) Souche de lactobacillus acidophilus kbl409 et son utilisation
KR101985792B1 (ko) 항비만 활성을 갖는 인체 유래 락토바실러스 퍼멘툼 mg4231 또는 락토바실러스 퍼멘툼 mg4244 균주 및 이를 포함하는 조성물
WO2017047968A1 (fr) Nouveau lactobacillus présentant diverses fonctions et son utilisation
WO2020262755A1 (fr) Nouvelle composition probiotique pour la régulation de l'immunité intestinale
WO2021221398A1 (fr) Nouvelles bactéries d'acide lactique ayant un excellent effet d'amélioration de la fonction immunitaire, et composition alimentaire, composition alimentaire fonctionnelle pour la santé et probiotiques les comprenant
WO2021261632A1 (fr) Nouvelle souche de faecalibacterium prausnitzii eb-fpdk11 et utilisation associée
WO2020091312A1 (fr) Composition contenant des probiotiques en tant que principe actif pour prévenir ou traiter des lésions intestinales causées par la consommation d'alcool
WO2020116962A1 (fr) Composition de prévention, d'amélioration, ou de traitement du diabète, comprenant le produit de fermentation de bactéries acide lactique d'extrait de paeonia lactiflora comme ingrédient actif
WO2017047962A1 (fr) Nouveau lactobacillus et composition pour prévenir, atténuer ou traiter des maladies cérébrales dégénératives ou des troubles de la fonction cognitive
WO2010087577A2 (fr) Utilisation d'extrait de thymus capitatus, d'extrait de satureja hortensis, ou de carvacrol pour traiter des maladies métaboliques
WO2016072655A1 (fr) Composition pour améliorer, traiter ou prévenir la constipation comprenant un produit fermenté renfermant des bactéries lactiques de graines de cassia comme ingrédient efficace, et son procédé de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15749693

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15749693

Country of ref document: EP

Kind code of ref document: A1